• Investing
  • Stock
  • Editor’s Pick
  • Economy
The Significant Deals
Editor's Pick

US imposing new export controls on biotech equipment over China concerns

by January 15, 2025
written by January 15, 2025

By David Shepardson

WASHINGTON (Reuters) – The U.S. Commerce Department said Wednesday it is imposing new export controls on biotechnology equipment and related technology because of national security concerns tied to artificial intelligence and data science.

Washington has raised concerns that China could use U.S. technology to strengthen military capabilities and help design new weapons through AI. The department said the laboratory equipment could be used for “human performance enhancement, brain-machine interfaces, biologically-inspired synthetic materials, and possibly biological weapons.”

The new export controls, which restrict shipments to China and other countries without a U.S. license, are for high-parameter flow cytometers and certain mass spectrometry equipment, which Commerce said can “generate high-quality, high-content biological data, including that which is suitable for use to facilitate the development of AI and biological design tools.”

This is the latest effort by Washington to restrict U.S. technology to China. On Monday, Commerce moved to further restrict AI chip and technology exports from China aimed at helping the United States maintain its dominant status in AI by controlling it around the world.

U.S. lawmakers have been considering a number of proposals to keep Americans’ personal health and genetic information from foreign adversaries and aim to push U.S. pharmaceutical and biotech companies to lessen their reliance on China for everything from drug ingredient manufacturing to early research.

Last week, U.S. lawmakers called on the Commerce Department to consider restricting the export of U.S. biotechnology to the Chinese military, citing concerns Beijing could weaponize it.

The Chinese Embassy in Washington last week said Beijing “firmly opposes any country’s development, possession or use of biological weapons.”

In August, U.S. lawmakers called on the Food and Drug Administration to ramp up scrutiny of U.S. clinical trials conducted in China, citing the risk of intellectual property theft and the possibility of forced participation of members of China’s Uyghur minority group.

This post appeared first on investing.com
0 comment
0
FacebookTwitterPinterestEmail

previous post
US health officials set to ban Red No. 3 food coloring- Bloomberg News
next post
Trump’s new SEC leadership poised to kick start crypto overhaul, sources say

You may also like

China central bank conducts 1.7 trln yuan of...

January 27, 2025

Fuji Media, rocked by sexual misconduct allegations, says...

January 27, 2025

ECB president fears loss of central bank independence

January 27, 2025

European tech shares tumble as China’s AI push...

January 27, 2025

Futures slip as investors eye China’s latest AI...

January 27, 2025

Markets may be repeating the mistake of 2019,...

January 27, 2025

How billionaire Caltagirone could influence Italy’s banking M&A...

January 27, 2025

How Italy’s MPS went from near collapse to...

January 27, 2025

Analysis-To weather Trump, emerging market investors look to...

January 27, 2025

Chinese AI startup DeepSeek overtakes ChatGPT on Apple...

January 27, 2025
Sign up and get the scoop before anyone else—fresh updates, and secret deals, all wrapped up just for you. We're talking juicy tips, fun surprises, and invites to events you actually want to go to. Don’t just watch from the sidelines—jump in and be part of the magic!








    By signing up, you're cool with getting emails from us. Don’t worry — your info stays safe, sound, and strictly confidential. No spam, no funny business. Just the good stuff.

    Recent Posts

    • Elon Musk’s SpaceX acquires xAI

      February 25, 2026
    • The architect of Amazon’s supply chain on running a startup with your spouse

      February 25, 2026
    • Trump administration alleges Nike discriminated against white workers

      February 25, 2026
    • Landmark trial accusing social media companies of addicting children to their platforms begins

      February 25, 2026

    Categories

    • Economy (245)
    • Editor's Pick (3,646)
    • Investing (688)
    • Stock (6,426)

    Latest News

    • Elon Musk’s SpaceX acquires xAI
    • The architect of Amazon’s supply chain on running a startup with your spouse

    Popular News

    • In the Market: How Harris, Trump promises could feed market’s addiction to the Fed
    • Sweden stocks lower at close of trade; OMX Stockholm 30 down 2.41%

    About The Significant deals

    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Copyright © 2026 thesignificantdeals.com | All Rights Reserved

    The Significant Deals
    • Investing
    • Stock
    • Editor’s Pick
    • Economy